Simcere Pharmaceutical Group (SCR) Misses Q2 EPS by 2c

August 10, 2012 6:30 AM EDT Send to a Friend
Get Alerts SCR Hot Sheet
Trade SCR Now!
Join SI Premium – FREE
Simcere Pharmaceutical Group (NYSE: SCR) reported Q2 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $86.83 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment